Facing strong opposition from a rare alliance of the pharma and tech industries as well as past agency leaders, the U.S. Patent and Trademark Office (USPTO) has withdrawn a proposed new rule directed at Terminal Disclaimer...more
12/10/2024
/ Corporate Counsel ,
Life Sciences ,
Obviousness-Type Double Patenting (ODP) ,
Patent Applications ,
Patent Portfolios ,
Patents ,
Pharmaceutical Industry ,
Proposed Rules ,
Technology ,
Terminal Disclaimer ,
USPTO